AMRINONE LACTATE Drug Patent Profile

Which patents cover Amrinone Lactate, and when can generic versions of Amrinone Lactate launch?

Amrinone Lactate is a drug marketed by Baxter Hlthcare Corp, Hikma, and Hospira. and is included in three NDAs.

The generic ingredient in AMRINONE LACTATE is inamrinone lactate. There is one drug master file entry for this compound. Additional details are available on the inamrinone lactate profile page.

Summary for AMRINONE LACTATE

US Patents:	0
Applicants:	3
NDAs:	3
Raw Ingredient (Bulk) Api Vendors:	1
Patent Applications:	131
DailyMed Link:	AMRINONE LACTATE at DailyMed

US Patents and Regulatory Information for AMRINONE LACTATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Baxter Hlthcare Corp	AMRINONE LACTATE	inamrinone lactate	INJECTABLE;INJECTION	075542-001	May 10, 2000		DISCN	No	No
Hikma	AMRINONE LACTATE	inamrinone lactate	INJECTABLE;INJECTION	075513-001	May 9, 2000		RX	No	Yes
Hospira	AMRINONE LACTATE	inamrinone lactate	INJECTABLE;INJECTION	074616-001	Aug 3, 1998		DISCN	No	No

Amrinone Lactate Market Dynamics, Patent Status, FDA History, and Financial Outlook

Last updated: September 9, 2026

Amrinone lactate, also known as inamrinone, is a legacy intravenous phosphodiesterase-3 inhibitor for short-term treatment of severe congestive heart failure. Its commercial position has deteriorated substantially because of adverse-effect concerns, limited duration of use, generic competition, and substitution by milrinone and other heart-failure therapies. The U.S. product has no meaningful publicly reported standalone revenue base, no active branded exclusivity position, and limited strategic value for large pharmaceutical companies.

What is the current market status of amrinone lactate?

Amrinone lactate is a mature, low-volume hospital injectable rather than a growth pharmaceutical market.

The drug was marketed in the United States under the brand name Inocor. Its approved use was short-term intravenous treatment of congestive heart failure in patients who had not responded adequately to conventional therapy. The product required inpatient administration and cardiac monitoring, limiting its use to acute-care settings.[1]

Current market characteristics include:

Market factor	Assessment
Active ingredient	Amrinone lactate, also called inamrinone
Drug class	Phosphodiesterase-3 inhibitor
Primary setting	Hospital and intensive-care use
Dosage form	Intravenous injection
Original branded product	Inocor
U.S. market status	Legacy/discontinued branded product with limited commercial visibility
Generic competition	Present or historically available in injectable form, depending on jurisdiction
Main substitute	Milrinone lactate
Retail market	Essentially absent
Public standalone revenue	Not separately disclosed
Biosimilar exposure	Not applicable
Patent-based pricing power	Minimal

The market is driven by hospital formulary decisions, emergency supply requirements, and specialist familiarity rather than outpatient prescribing or direct-to-consumer demand.

When did amrinone lactate lose exclusivity?

Amrinone lactate lost practical market exclusivity decades ago. Its U.S. approval dates to the early period of modern intravenous inotropic therapy, and any original composition-of-matter or formulation protection has long expired. Public FDA records do not indicate a current active patent estate that supports branded exclusivity for amrinone lactate.[2]

The commercial loss of exclusivity occurred before the modern Orange Book litigation framework became a major feature of pharmaceutical launches. As a result, the principal competitive issue is generic supply and clinical substitution, not an approaching patent cliff.

Does amrinone lactate have active Orange Book patents?

No material active Orange Book patent protection is associated with the legacy Inocor product based on FDA Orange Book records and current product listings.[2] The product does not have the patent profile of a recently approved small-molecule therapy.

The relevant regulatory position is:

• No current branded patent moat is evident.
• No meaningful pediatric-exclusivity strategy is associated with the product.
• No new chemical entity exclusivity remains.
• No recognized regulatory exclusivity period supports premium pricing.
• Any present competition depends primarily on manufacturing capability, quality compliance, and hospital procurement.

What patents protect amrinone lactate?

No active patent family with material commercial relevance has been identified for amrinone lactate in the United States.

Historical patent protection may have covered the compound, pharmaceutical compositions, or therapeutic use. Those rights would have expired given the age of the product. A patent search for current commercial purposes should focus on:

1. Formulation and stability claims for injectable amrinone lactate.
2. Manufacturing processes for pharmaceutical-grade active ingredient.
3. Container-closure systems and preservative systems.
4. Hospital-ready presentation, including premixed bags or ready-to-use syringes.
5. Combination use with other inotropes or hemodynamic therapies.

These categories could create narrow protection in a particular jurisdiction, but they would not recreate broad product exclusivity unless a valid, enforceable, unexpired claim covers the marketed product.

Are there formulation patents for amrinone lactate?

The principal commercial formulation is an injectable lactate salt. Formulation value is limited because the product is an established parenteral dosage form with no evident proprietary delivery system.

A new formulation could theoretically obtain patent protection if it produced a non-obvious improvement in stability, concentration, compatibility, storage, or administration. Such a patent would protect only the claimed formulation and would not necessarily block conventional amrinone lactate injection.

The absence of a differentiated delivery system limits opportunities to convert amrinone lactate into a higher-value specialty product.

What is the FDA regulatory status of amrinone lactate?

Amrinone was approved as an intravenous treatment for severe heart failure. The FDA-approved labeling identifies several clinically significant safety concerns, including hypotension, arrhythmias, thrombocytopenia, gastrointestinal effects, and potential hepatic toxicity.[1]

The labeled use was short term. The drug was not positioned as a chronic outpatient heart-failure therapy, which sharply limits prescription volume and commercial durability.

The regulatory profile is summarized below:

Regulatory issue	Status
FDA pathway	Legacy 505(b)(1)-type approval history associated with Inocor
Approved route	Intravenous
Approved setting	Short-term hospital treatment
Chronic outpatient use	Not the primary labeled use
Safety monitoring	Hemodynamic and laboratory monitoring required
Current branded commercial position	No meaningful branded market presence
Regulatory reapproval opportunity	Possible only through a new sponsor and applicable FDA pathway
Product differentiation	Limited without a new formulation or delivery technology

Amrinone was later referred to as inamrinone in clinical practice to reduce medication-name confusion with amiodarone. The change did not create a new commercial franchise.

How does amrinone lactate compare with milrinone?

Milrinone is the principal pharmacologic and commercial comparator. Both drugs are PDE3 inhibitors with positive inotropic and vasodilatory effects, but milrinone achieved broader and more durable hospital adoption.

Attribute	Amrinone lactate	Milrinone lactate
Common name	Inamrinone	Milrinone
Drug class	PDE3 inhibitor	PDE3 inhibitor
Route	Intravenous	Intravenous
Clinical role	Short-term inotropic support	Short-term inotropic support
Market position	Legacy and limited	Established generic hospital product
Safety concerns	Hypotension, thrombocytopenia, hepatic effects	Hypotension, arrhythmias, dose adjustment in renal impairment
Commercial scale	Low and opaque	Larger hospital market
Formulary competition	Usually disadvantaged	Common substitute or preferred agent
Patent position	Expired or immaterial	Mature generic position

Milrinone is generally more important in contemporary hospital formularies. Clinical familiarity, established dosing protocols, and broader supplier participation have reduced the addressable market for amrinone.

What generic entry risks exist for amrinone lactate?

Generic entry risk is no longer an emerging event. It is the historical condition of the market.

For any remaining branded or authorized-generic supply, competitive risks include:

• Price erosion from injectable generic manufacturers.
• Hospital conversion to milrinone.
• Tender-based procurement.
• Supply interruptions caused by low manufacturing volumes.
• Relabeling or sourcing changes by wholesalers.
• Compounding or alternative institutional supply channels where legally permitted.
• Declining clinical familiarity among new prescribers.

A Paragraph IV challenge would have limited strategic relevance unless a sponsor filed a new patent covering a reformulated or differentiated product. With no meaningful current patent barrier, a standard generic applicant would generally pursue an ANDA route rather than challenge an active patent estate.

Which companies are challenging amrinone lactate patents?

No material current Paragraph IV campaign or high-profile patent litigation involving amrinone lactate is evident in the public U.S. record. The product’s commercial decline occurred after its core exclusivity expired, leaving little economic incentive for litigation.

Competition is more likely to arise through:

• ANDA approvals;
• hospital contracting;
• active pharmaceutical ingredient sourcing;
• manufacturing capacity;
• regulatory compliance; and
• substitution with milrinone.

What patent litigation affects amrinone lactate?

No significant active U.S. patent litigation affecting amrinone lactate has been identified in the principal public regulatory and litigation sources reviewed for this analysis.[2,3]

The absence of litigation is commercially meaningful. It indicates that the key barriers are operational rather than legal. A potential entrant would focus on FDA quality requirements, validated sterile manufacturing, supply reliability, and hospital purchasing rather than patent settlement negotiations.

Are there settlement agreements involving amrinone lactate?

No major public patent settlement agreement involving amrinone lactate has been identified. The product is too mature and commercially limited to support the type of branded-generic settlement commonly seen for high-revenue medicines.

There is also no evident delayed generic-entry structure comparable to agreements involving major cardiovascular or oncology products.

What is the financial trajectory for amrinone lactate?

The financial trajectory is one of long-term contraction, with no reliable public evidence of a recoverable branded revenue stream.

Historical revenue phase

Amrinone benefited from an earlier period in which intravenous inotropes were used more broadly for severe heart failure. Revenue was supported by hospital use and the absence of strong generic alternatives.

Erosion phase

Sales declined as:

• Safety concerns reduced physician preference.
• Milrinone gained acceptance.
• The use of chronic inotropic therapy became more selective.
• Generic competition compressed pricing.
• The branded Inocor franchise lost commercial relevance.
• Hospitals consolidated purchasing around fewer injectable suppliers.

Current phase

The current market is best characterized as a small, fragmented, price-sensitive injectable market. Public companies do not generally report amrinone lactate revenue as a separate line item. The product may contribute immaterial revenue within a broader hospital-generic portfolio, but there is no dependable public basis for estimating a standalone annual market size.

Financial indicator	Current assessment
Standalone global sales	Not publicly disclosed
U.S. branded sales	No meaningful current branded franchise
Price trend	Long-term downward pressure
Volume trend	Low and structurally declining
Gross-margin outlook	Dependent on manufacturing scale and supply scarcity
Commercial investment case	Weak without reformulation or supply disruption
Licensing value	Low for the legacy product
Acquisition value	Limited to portfolio or manufacturing strategy

A temporary shortage could increase spot pricing, but shortages would not necessarily improve long-term franchise value. The product lacks durable differentiation and would remain exposed to substitution once supply normalizes.

What licensing deals involve amrinone lactate?

No major current licensing transaction involving amrinone lactate has been identified. The molecule’s age, generic status, limited market size, and clinical substitution reduce the likelihood of a meaningful royalty-bearing license.

A transaction could still occur in narrow circumstances, such as:

• Acquisition of a hospital-injectable portfolio.
• Transfer of an approved abbreviated product.
• Licensing of a sterile manufacturing process.
• Regional commercialization rights in a market with limited milrinone access.
• Supply agreements tied to institutional procurement.

The economic value of such a transaction would likely derive from manufacturing and distribution infrastructure rather than from the active ingredient’s intellectual property.

How strong is the patent estate for amrinone lactate?

The patent estate is weak for commercial purposes.

Patent-estate criterion	Assessment
Composition-of-matter protection	Expired
Active Orange Book patents	None of material commercial significance identified
Formulation protection	Limited or absent for the conventional injection
Method-of-use protection	Historical claims would be expired or commercially narrow
Manufacturing protection	Potentially relevant only for specific processes
Patent litigation leverage	Low
Freedom-to-operate complexity	Generally low for the legacy molecule, subject to jurisdiction-specific review
Differentiation potential	Requires new formulation, device, or treatment protocol

The strongest potential barrier is not a classic product patent. It is sterile manufacturing capability combined with regulatory approval and dependable supply.

What generic launch scenarios exist for amrinone lactate?

A new entrant would face three plausible commercial scenarios.

Standard low-price generic

The sponsor would market conventional amrinone lactate injection through hospital distributors. This strategy would require limited promotional spending but would face low volume and price competition.

Supply-constrained premium generic

A manufacturer with reliable sterile capacity could obtain better pricing during shortages or when incumbent suppliers withdraw. This position would depend on supply continuity, not patent protection.

Reformulated hospital product

A sponsor could develop a premixed bag, ready-to-use syringe, improved stability profile, or simplified dosing presentation. A new product could seek formulation or device claims and potentially qualify for a higher price, but the addressable market would remain small.

What are the manufacturing and intellectual-property barriers?

Manufacturing is the principal practical barrier.

Amrinone lactate injection requires validated sterile production, appropriate container-closure systems, stability data, extractables and leachables assessment, particulate control, and ongoing compliance with FDA current good manufacturing practices. A small market can make these fixed costs difficult to recover.

The active ingredient itself is unlikely to create a major technical barrier. The commercial risk lies in maintaining:

• Qualified API supply;
• sterile fill-finish capacity;
• validated shipping and storage conditions;
• consistent hospital-grade quality;
• regulatory documentation; and
• adequate inventory to avoid stockouts.

These factors can support short-term pricing power but do not create durable exclusivity.

What is the likely future of the amrinone lactate market?

The base case is continued market contraction and niche hospital availability. Amrinone lactate is unlikely to regain broad commercial relevance without a clinical or formulation change that addresses its disadvantages relative to milrinone.

The most probable outcomes are:

1. Continued use in selected institutions or regions.
2. Further generic supplier consolidation.
3. Periodic supply disruptions.
4. Replacement by milrinone where clinically appropriate.
5. No meaningful patent-driven price recovery.
6. Limited licensing and acquisition activity.
7. Possible discontinuation in markets where manufacturing economics deteriorate.

A commercial revival would require evidence of a differentiated clinical benefit, a new delivery format, or a supply gap large enough to support investment. The legacy molecule alone does not provide that basis.

Key Takeaways

• Amrinone lactate, or inamrinone, is a mature intravenous PDE3 inhibitor with a shrinking hospital market.
• Inocor’s branded exclusivity has expired, and no material active Orange Book patent position is evident.
• The product has no significant current Paragraph IV or patent-litigation exposure.
• Milrinone is the main clinical and commercial substitute.
• Public companies do not disclose a reliable standalone revenue figure for amrinone lactate.
• The market’s principal barriers are sterile manufacturing, supply reliability, and regulatory compliance.
• Long-term financial prospects are weak without a differentiated formulation or a temporary supply shortage.
• Biosimilar risk does not apply because amrinone lactate is a small-molecule drug, not a biologic.
• Any new commercial opportunity would likely involve a hospital-ready formulation, regional supply strategy, or generic injectable portfolio acquisition.

FAQs

Is amrinone lactate still FDA approved?

Amrinone was historically FDA approved as Inocor for short-term intravenous treatment of severe heart failure. The current branded commercial status is limited, and product availability depends on jurisdiction and supplier activity.[1,2]

Is amrinone lactate the same as inamrinone?

Yes. Inamrinone is the later clinical name for amrinone. The name change was adopted to reduce confusion with amiodarone.

Can a generic company file a Paragraph IV for amrinone lactate?

A Paragraph IV filing would generally require an active patent listed for the reference product. Because the relevant legacy exclusivity has expired and no material active Orange Book patent has been identified, a conventional ANDA strategy would be more relevant than a Paragraph IV challenge.

Does amrinone lactate have biosimilar competition?

No. Biosimilar regulation applies to biologic products. Amrinone lactate is a chemically synthesized small molecule and is subject to generic-drug, not biosimilar, competition.

Is amrinone lactate a viable pharmaceutical licensing asset?

As a standalone molecule, it has limited licensing value. Its potential value is more likely to arise from sterile manufacturing capacity, regional distribution rights, an approved injectable product, or a differentiated formulation.

References

1. U.S. Food and Drug Administration. (n.d.). Inocor (amrinone lactate) injection prescribing information. FDA/DailyMed labeling archive.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs database. FDA.